Cargando…

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer

Large independent analyses on cancer cell lines followed by functional studies have identified Schlafen 11 (SLFN11), a putative helicase, as the strongest predictor of sensitivity to DNA-damaging agents (DDAs), including platinum. However, its role as a prognostic biomarker is undefined, partially d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winkler, Claudia, King, Matthew, Berthe, Julie, Ferraioli, Domenico, Garuti, Anna, Grillo, Federica, Rodriguez-Canales, Jaime, Ferrando, Lorenzo, Chopin, Nicolas, Ray-Coquard, Isabelle, Delpuech, Oona, Bedognetti, Davide, Ballestrero, Alberto, Leo, Elisabetta, Zoppoli, Gabriele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492341/ https://www.ncbi.nlm.nih.gov/pubmed/34549724 http://dx.doi.org/10.1172/jci.insight.146098

Ejemplares similares

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
por: Nogales, Vanesa, et al.
Publicado: (2015)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
por: Tserpeli, Victoria, et al.
Publicado: (2021)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
por: Winkler, Claudia, et al.
Publicado: (2020)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
por: Xu, Qiao Ping, et al.
Publicado: (2023)

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
por: Willis, Sophie E., et al.
Publicado: (2021)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Cirmena, Gabriella, et al.
Publicado: (2022)

Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma
por: Ferrando, Lorenzo, et al.
Publicado: (2020)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer
por: Brown, David N., et al.
Publicado: (2016)

Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Cirmena, Gabriella, et al.
Publicado: (2020)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
por: Isnaldi, Edoardo, et al.
Publicado: (2019)

Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin
por: Peng, Yaojun, et al.
Publicado: (2019)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer
por: Dameri, Martina, et al.
Publicado: (2021)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
por: Zoppoli, Gabriele, et al.
Publicado: (2017)

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
por: Kahramanoğlu, İlker, et al.
Publicado: (2018)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Characterization of Novel Ribosome-Associated Endoribonuclease SLFN14 from Rabbit Reticulocytes
por: Pisareva, Vera P., et al.
Publicado: (2015)

Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL
por: Goldshtein, Aviya, et al.
Publicado: (2016)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Role of the novel endoribonuclease SLFN14 and its disease-causing mutations in ribosomal degradation
por: Fletcher, Sarah J., et al.
Publicado: (2018)

Novel SLFN14 mutation associated with macrothrombocytopenia in a patient with severe haemorrhagic syndrome
por: Polokhov, Dmitrii, et al.
Publicado: (2023)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_af8gavogb96ekjo90h27410lfh